Comparing BioLargo (BLGO) and Its Competitors

BioLargo (NASDAQ:BLGOGet Free Report) is one of 33 publicly-traded companies in the “Chemicals & allied products” industry, but how does it contrast to its peers? We will compare BioLargo to similar companies based on the strength of its dividends, analyst recommendations, risk, profitability, institutional ownership, earnings and valuation.

Profitability

This table compares BioLargo and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioLargo -16.53% -58.35% -32.12%
BioLargo Competitors -591.84% 5.15% -0.65%

Analyst Ratings

This is a breakdown of recent ratings for BioLargo and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLargo 0 0 0 0 N/A
BioLargo Competitors 139 1250 1568 44 2.51

As a group, “Chemicals & allied products” companies have a potential upside of 15.66%. Given BioLargo’s peers higher probable upside, analysts clearly believe BioLargo has less favorable growth aspects than its peers.

Valuation and Earnings

This table compares BioLargo and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioLargo $12.23 million -$3.50 million -8.00
BioLargo Competitors $6.85 billion $211.64 million 66.88

BioLargo’s peers have higher revenue and earnings than BioLargo. BioLargo is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

0.0% of BioLargo shares are held by institutional investors. Comparatively, 68.3% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by company insiders. Comparatively, 10.3% of shares of all “Chemicals & allied products” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

BioLargo has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500. Comparatively, BioLargo’s peers have a beta of 1.81, indicating that their average share price is 81% more volatile than the S&P 500.

Summary

BioLargo peers beat BioLargo on 8 of the 10 factors compared.

BioLargo Company Profile

(Get Free Report)

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

Receive News & Ratings for BioLargo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLargo and related companies with MarketBeat.com's FREE daily email newsletter.